Skip to main content
. 2021 Jan 15;16(5):484–490. doi: 10.1159/000512840

Table 2.

Patient perception of tamoxifen

Symptom duration, months 22.4 (6–24)
Time to treatment of those patients
operated in the adherence assessment period, months
5.7 (0.1–10.8)
Questionnaire
What is the most important medical problem for women in this area? (n = 22)
 “No idea” 14 (64)
 Back pain 3 (14)
 Cervical cancer 3 (14)
 Mastitis 1 (4)
 Gastritis 1 (4)
What is cancer? (n = 22)
 “No idea” 11 (50)
 Disease 5 (23)
 Deadly disease 6 (27)
Do you have cancer? (n = 20)
 No 10 (50)
 Yes 10 (50)
Is tamoxifen necessary? (n = 19)
 No 0 (0)
 Yes 19 (100)
Would you pay for tamoxifen? (n = 14)
 No 11 (79)
 Yes 3 (21)
Wherefore do you take tamoxifen? (n = 17)
 “No idea” 6 (35)
 Prevents cancer 9 (53)
 Is helpful 1 (6)
 Minders the power of cancer 1 (6)
Why did you stop taking tamoxifen? (n = 9)
 Terminal illness 2 (22)
 Difficult circumstances 2 (22)
 Lack of money 2 (22)
 Side effects of therapy 2 (22)
 Unknown 1 (11)
Describe complaints on your health (n = 20; more than one answer possible)
 None 14 (41)
 Nausea 3 (9)
 Hot flushes 3 (9)
 Sweating 6 (18)
 Vaginal discharge 1 (3)
 Diarrhea 1 (3)
 Changes in mood 2 (5)
 Other 4 (12)
Describe discomforts with the taking of tamoxifen (n = 21; more than one answer possible)
 “No problems” 14 (59)
 Difficult to swallow 7 (29)
 Interrupts daily work 2 (8)
 Reminds of the disease 1 (4)

Data are presented as the mean (IQR) or number of answering patients (%). n = 22 of 26 who initiated tamoxifen; families of 3 deceased patients were not found, and 1 husband was unable to answer the questionnaire